Yuebin Liang
Overview
Explore the profile of Yuebin Liang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
210
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yao Y, Lv Y, Tong L, Liang Y, Xi S, Ji B, et al.
Brief Bioinform
. 2022 Oct;
23(6).
PMID: 36242564
Breast cancer patients often have recurrence and metastasis after surgery. Predicting the risk of recurrence and metastasis for a breast cancer patient is essential for the development of precision treatment....
2.
Xu J, Meng Y, Peng L, Cai L, Tang X, Liang Y, et al.
J Cell Mol Med
. 2022 Jun;
26(13):3772-3782.
PMID: 35644992
Amid the COVID-19 crisis, we put sizeable efforts to collect a high number of experimentally validated drug-virus association entries from literature by text mining and built a human drug-virus association...
3.
Lang J, Li Y, Yang W, Dong R, Liang Y, Liu J, et al.
BMC Genomics
. 2022 Apr;
23(Suppl 1):316.
PMID: 35443609
Background: Drug-resistant bacteria are important carriers of antibiotic-resistant genes (ARGs). This fact is crucial for the development of precise clinical drug treatment strategies. Long-read sequencing platforms such as the Oxford...
4.
Yang J, Ju J, Guo L, Ji B, Shi S, Yang Z, et al.
Comput Struct Biotechnol J
. 2022 Jan;
20:333-342.
PMID: 35035786
HER2-positive breast cancer is a highly heterogeneous tumor, and about 30% of patients still suffer from recurrence and metastasis after trastuzumab targeted therapy. Predicting individual prognosis is of great significance...
5.
Xie X, Wang X, Liang Y, Yang J, Wu Y, Li L, et al.
Front Oncol
. 2021 Dec;
11:763527.
PMID: 34900711
Many diseases are accompanied by changes in certain biochemical indicators called biomarkers in cells or tissues. A variety of biomarkers, including proteins, nucleic acids, antibodies, and peptides, have been identified....
6.
Pang H, Zhang G, Yan N, Lang J, Liang Y, Xu X, et al.
Front Oncol
. 2021 Dec;
11:738222.
PMID: 34868931
Tamoxifen (TAM) is the most commonly used adjuvant endocrine drug for hormone receptor-positive (HR+) breast cancer patients. However, how to accurately evaluate the risk of breast cancer recurrence and metastasis...
7.
Yang Y, Yang J, Liang Y, Liao B, Zhu W, Mo X, et al.
Front Genet
. 2021 Feb;
12:642981.
PMID: 33633793
Cancer immunotherapy, as a novel treatment against cancer metastasis and recurrence, has brought a significantly promising and effective therapy for cancer treatments. At present, programmed death 1 (PD-1) and programmed...
8.
Wu Z, Wang L, Li C, Cai Y, Liang Y, Mo X, et al.
Front Genet
. 2020 Nov;
11:768.
PMID: 33193560
It is critical for patients who cannot undergo eradicable surgery to predict the risk of lung cancer recurrence and metastasis; therefore, the physicians can design the appropriate adjuvant therapy plan....
9.
He B, Lu Q, Lang J, Yu H, Peng C, Bing P, et al.
Front Bioeng Biotechnol
. 2020 Aug;
8:897.
PMID: 32850745
Circulating tumor cells (CTCs) derived from primary tumors and/or metastatic tumors are markers for tumor prognosis, and can also be used to monitor therapeutic efficacy and tumor recurrence. Circulating tumor...
10.
He B, Zhang Y, Zhou Z, Wang B, Liang Y, Lang J, et al.
Front Bioeng Biotechnol
. 2020 Aug;
8:737.
PMID: 32850691
Sequencing-based identification of tumor tissue-of-origin (TOO) is critical for patients with cancer of unknown primary lesions. Even if the TOO of a tumor can be diagnosed by clinicopathological observation, reevaluations...